ストックスクリーナーアプリを入手
11.94
7.09%
0.79
アフターアワーズ：
11.90
-0.04
-0.34%
Nuvectis Pharma Inc (NVCT) 最新ニュース
NVCT Q1 2026 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue StatusRevenue Per Share - newsline.com
NVCT Maintained by HC Wainwright & Co. -- Price Target Raised to $13.00 - GuruFocus
Nuvectis Shareholders Approve Director Election and Auditor Ratification - TipRanks
Nuvectis Pharma (NVCT) director granted 35,000 restricted common shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted shares, now holds 122,828 - Stock Titan
Nuvectis Pharma (NVCT) grants director Juan Sanchez 35,000 restricted shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted common shares in Form 4 filing - Stock Titan
[8-K] Nuvectis Pharma, Inc. Reports Material Event - Stock Titan
Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright - TipRanks
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Cost DisciplinePost-Earnings Reaction - newsline.com
Nuvectis Pharma (NVCT) Rallies 1.94% as Stock Tests Key Resistance at $11.04Long Short Pair - newsline.com
Analyst Reiterates Buy on Nuvectis Pharma, Maintains $17 Price Target on NXP900 Pipeline Upside and Favorable M&A Read‑Through - TipRanks
(NVCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances PipelineProfit Inflection Point - newsline.com
NVCT Q1 2026 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Analysis - newsline.com
Responsive Playbooks and the NVCT Inflection - Stock Traders Daily
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesSlow Growth Warning - The Legal Advocate
Nuvectis Pharma (NVCT) Declines 5.39% as Stock Tests Key Support LevelIchimoku Cloud - thelegaladvocate.com
Wall Street analysts think Nuvectis Pharma (NVCT) could surge 57%: Read this before placing a bet - MSN
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet - sharewise.com
NVCT Q1 2026 Earnings: Better-than-Expected Loss Narrower as Company Advances PipelineRevenue Growth Outlook - newsline.com
Nuvectis Pharma (NVCT) Surges +2.82%, Nearing $11.48 Resistance 2026-05-21IV Contraction - Newser
Understanding the Setup: (NVCT) and Scalable Risk - Stock Traders Daily
NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma set to participate in key investor event at NASDAQ - Traders Union
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor ... - Caledonian Record
Number of shareholders of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Number of shareholders of Nuvectis Pharma, Inc. – BOATS:NVCT - TradingView
TradingKey - TradingKey
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN
The Technical Signals Behind (NVCT) That Institutions Follow - Stock Traders Daily
What Nuvectis Pharma (NVCT) does that creates lasting value (Creeps Higher) 2026-05-08Momentum Investing - newser.com
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvectis Pharma | 10-Q: Q1 2026 Earnings Report - Moomoo
Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary - TradingView
Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsSEC.gov - SEC.gov
Nuvectis Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvectis Pharma posts first quarter 2026 financial results and business update - Traders Union
Cancer drug developer targets summer data as cash drops to $25.1M - Stock Titan
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma - Yahoo Finance
NVCT (Nuvectis Pharma) posts narrow Q4 2025 EPS miss, edging down 0.23% in muted investor reaction.Open Stock Picks - newser.com
Nuvectis Pharma Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
NVCT Forecast, Price Target & Analyst Ratings | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma (NVCT) Stock: Technical Risk Signals | Q4 2025: Below ExpectationsCommunity Risk Signals - Newser
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):